{
  "date": "2026-02-24",
  "items": [
    {
      "id": "1",
      "headline": "Six RNAi companies to keep an eye on in 2026",
      "preview": "This article highlights six promising RNAi biotech companies making strides in various disease areas.",
      "article": "Over the past two decades, RNA interference (RNAi) has emerged as one of biotech\u2019s most powerful approaches for targeting disease at its genetic root. This article highlights six RNAi biotech companies helping to drive momentum in the field, including Aerska, ADARx Pharmaceuticals, Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, City Therapeutics, and SanegeneBio.\n\nWhy this matters: These companies are developing innovative therapies that could address previously 'undruggable' targets, potentially transforming treatment options for conditions ranging from neurological disorders to rare genetic diseases. Their advancements in RNAi technology could lead to significant breakthroughs in personalized medicine and targeted therapies.",
      "sources": [
        {
          "name": "Labiotech.eu",
          "url": "https://www.labiotech.eu/best-biotech/rnai-companies/",
          "type": "news",
          "verified_date": "2026-02-23"
        }
      ]
    },
    {
      "id": "2",
      "headline": "FDA fleshes out new roadmap for testing personalized therapies",
      "preview": "The FDA has released new guidelines to facilitate the development of personalized therapies for rare diseases.",
      "article": "The FDA has announced new guidelines aimed at streamlining the approval process for personalized therapies targeting ultra-rare diseases. This initiative follows the successful treatment of KJ Muldoon, the first patient to receive a CRISPR-based therapy for a rare genetic condition. The new framework allows for a single well-controlled clinical investigation to support approval, addressing the challenges faced by families of patients with rare diseases.\n\nWhy this matters: This guidance could significantly accelerate the development of personalized treatments, making it easier for drug developers to bring innovative therapies to market for conditions that currently lack effective treatments. The FDA's approach aims to enhance patient access to potentially life-saving therapies.",
      "sources": [
        {
          "name": "BioPharma Dive - Latest News",
          "url": "https://www.biopharmadive.com/news/fda-guidance-personalized-therapies-rare-diseases-hhs/812890/",
          "type": "news",
          "verified_date": "2026-02-23"
        }
      ]
    },
    {
      "id": "3",
      "headline": "MoonLake\u2019s sonelokimab shows strong Phase II efficacy in axSpA",
      "preview": "MoonLake Immunotherapeutics reports promising Phase II trial results for sonelokimab in axSpA.",
      "article": "MoonLake Immunotherapeutics has announced that 81% of patients treated with sonelokimab in a Phase II trial met the ASAS40 response criteria for axial spondyloarthritis (axSpA). This single-domain antibody fragment targets IL-17A and IL-17F, cytokines implicated in inflammatory processes. The results suggest that sonelokimab may offer a competitive alternative to UCB\u2019s Bimzelx, which has already been approved for axSpA.\n\nWhy this matters: The strong efficacy results from this trial could position sonelokimab as a significant player in the treatment landscape for axSpA, potentially providing patients with a new therapeutic option in a market dominated by existing therapies.",
      "sources": [
        {
          "name": "European Biotechnology Magazine",
          "url": "https://european-biotechnology.com/latest-news/moonlakes-sonelokimab-shows-strong-phase-ii-efficacy-in-axspa-challenging-ucbs-bimzelx/",
          "type": "news",
          "verified_date": "2026-02-23"
        }
      ]
    },
    {
      "id": "4",
      "headline": "Pomegranate Leaf-Derived Natural Compound Inhibits Disease-Causing Amyloid Formation",
      "preview": "Researchers have identified a natural compound from pomegranate leaves that disrupts amyloid fibrils in TTR amyloidosis.",
      "article": "A study from Kumamoto University has discovered that a compound derived from pomegranate leaves, 1,2,3,4,6-penta-O-galloyl-\u03b2-D-glucose (PGG), can dismantle harmful amyloid fibrils associated with transthyretin (TTR) amyloidosis. This finding represents a significant advancement over existing treatments that primarily focus on preventing amyloid formation rather than clearing existing deposits.\n\nWhy this matters: The ability of PGG to selectively disrupt TTR amyloid aggregates could lead to new therapeutic strategies for treating TTR amyloidosis, a condition that currently lacks effective pharmacological interventions for reversing accumulated pathology.",
      "sources": [
        {
          "name": "BIOENGINEER.ORG",
          "url": "https://bioengineer.org/pomegranate-leaf-derived-natural-compound-inhibits-disease-causing-amyloid-formation/",
          "type": "news",
          "verified_date": "2026-02-24"
        }
      ]
    },
    {
      "id": "5",
      "headline": "Could sleep engineering be used to combat PTSD and depression?",
      "preview": "A new study explores the potential of sleep engineering techniques to treat PTSD and depression.",
      "article": "Recent research discusses the concept of sleep engineering, particularly targeted memory reactivation (TMR), as a promising therapeutic approach for conditions like PTSD and depression. By manipulating memories during sleep, TMR could strengthen positive memories and alter negative ones, potentially improving clinical outcomes for patients. The study emphasizes the need for careful consideration of dosage and potential adverse effects when applying these techniques.\n\nWhy this matters: If proven effective, sleep engineering could revolutionize treatment strategies for mental health disorders, offering new hope for individuals struggling with the debilitating effects of PTSD and depression.",
      "sources": [
        {
          "name": "PLOS Biology",
          "url": "https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3003633",
          "type": "paper",
          "verified_date": "2026-02-23"
        }
      ]
    }
  ]
}